Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.
Κonstantinos PorpodisIoanna TsiouprouApostolos ApostolopoulosPolyxeni NtontsiEvangelia FoukaDespoina PapakostaHarissios VliagoftisKalliopi DomvriPublished in: Journal of personalized medicine (2022)
Asthma phenotyping and endotyping are constantly evolving. Currently, several biologic agents have been developed towards a personalized approach to asthma management. This review will focus on different eosinophilic phenotypes and Th2-associated endotypes with eosinophilic inflammation. Additionally, airway remodeling is analyzed as a key feature of asthmatic eosinophilic endotypes. In addition, evidence of biomarkers is examined with a predictive value to identify patients with severe, uncontrolled asthma who may benefit from new treatment options. Finally, there will be a discussion on the results from clinical trials regarding severe eosinophilic asthma and how the inhibition of the eosinophilic pathway by targeted treatments has led to the reduction of recurrent exacerbations.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- chronic rhinosinusitis
- allergic rhinitis
- clinical trial
- cystic fibrosis
- rheumatoid arthritis
- air pollution
- oxidative stress
- early onset
- machine learning
- randomized controlled trial
- high throughput
- drug delivery
- cancer therapy
- deep learning
- phase ii
- drug induced
- decision making